19 Aug Shanth Thiyagalingam joins PainTEQ to lead commercialization of novel SI joint pain therapy
TAMPA, Fla., Aug. 18, 2020 /PRNewswire/ — Medical device innovator PainTEQ hired Shanth Thiyagalingam as its Chief Commercial Officer (CCO). PainTEQ is the creator of the LinQ™ SI Joint Stabilization System (pronounced “link”), a minimally invasive therapy for SI joint dysfunction.
Thiyagalingam oversees the company’s commercial strategy focused on sales, marketing and professional education with the goal of increasing patient access to the LinQ procedure, which relieves sacroiliac (SI) joint pain. Among various commercial initiatives, he will lead a training program to provide instruction and certification for doctors who want to incorporate LinQ into their practice.
“Patient and physician satisfaction with the novel LinQ system indicates that PainTEQ is poised to become the industry leader in treating chronic SI joint pain,” said Thiyagalingam. “We’re also fortunate to be working with an impressive roster of clinicians and other experts advocating across the country about the best-in-class benefits of LinQ.”
Thiyagalingam has nearly two decades of experience in the medical device and pharmaceutical industries. He most recently worked at Abbott as General Manager APAC Neuromodulation, where he led commercial efforts across Australia, Japan and Asia, targeted to alleviate chronic pain and movement disorders. He has also held key management positions at Nevro, Stryker, and St. Jude Medical.
“Shanth elevates our business to another level,” said PainTEQ CEO Sean LaNeve. “His clinical and business acumen give us the capabilities of a top tier medical device company. His presence and reputation in the market will allow us to scale our service to physicians and their patients across the country and beyond.”
About PainTEQ: Built to bring interventional procedures to market, PainTEQ is a medical device innovator headquartered in Tampa, Florida. Working with pain management specialists to safely reduce and eliminate sacroiliac (SI) joint dysfunction, PainTEQ’s LinQ therapy is immediately providing clinical benefits to individuals living with incapacitating lower back pain, through a minimally invasive, FDA-approved, outpatient procedure.
About LinQ: The LinQ SI Joint Stabilization System provides SI joint dysfunction patients with a safe, minimally invasive solution to combat pain. After a thorough diagnostic process, physicians can help alleviate, and in many cases eliminate, chronic pain by placing a single LinQ allograft into the SI Joint. This single implant helps patients immediately regain joint stability – and with its large graft window, the LinQ SI Joint Stabilization System helps create an ideal environment for long-term fusion. Learn more at PainTEQ.com.
*Editor note: Thiyagalingam headshot available here.
SOURCE: PainTEQ
, PR Newswire, 18th August 2020